Diagnosticos da America stock
Price history
+16.01% over the period1 year: from R$2.81 (November 19, 2025) to R$3.26 (November 19, 2026), +16.01%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 19, 2026 | R$3.26 |
| October 30, 2026 | R$2.98 |
| September 30, 2026 | R$4.02 |
| August 31, 2026 | R$2.61 |
| July 31, 2026 | R$2.61 |
| June 30, 2026 | R$2.71 |
| May 29, 2026 | R$3.10 |
| April 30, 2026 | R$3.38 |
| March 31, 2026 | R$2.92 |
| February 27, 2026 | R$4.03 |
| January 30, 2026 | R$4.26 |
| December 30, 2025 | R$4.54 |
| November 28, 2025 | R$3.14 |
| November 19, 2025 | R$2.81 |
At a glance
The company
Provides diagnostic and hospital services, including medical consultancy and franchise contracting, in Brazil and Argentina
Latest results
Quarter to September 30, 2026 · EPS R$0.05 (estimate R$0.01)
Next event
TickerLandia's take on Diagnosticos da America
- Strong point: Market momentum (80/100 in its group). Weak point: Profitability (11/100).
- “Value traps” (Brazil): No. 2 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−43.70% from the 52-week high
Analysts · 12 analysts
Average targetR$4.05+24.23% vs. price
Buy 4 · Hold 8 · Sell 0
TickerLandia Fingerprint: Diagnosticos da America
Compared with similar companies: very low price, very high risk, and very low profitability.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 317 Latin American stocks.
Pricevery low4
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 12.8 6 EV/EBITDA 8.88 6 Price/book 0.58 2 Price/sales 0.45 2 Profitabilityvery low11
How much it earns on revenue and capital.
Metric Value Position in group Net margin −9.0% 6 ROA 3.2% 17 Gross margin 30.5% 17 Operating margin 10.9% 17 ROE −10.7% 2 Earnings stabilitylow31
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.2% 57 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 6 Growthlow31
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −5.24% 2 Earnings growth (year over year) +67.80% 90 Revenue growth (year over year) −7.60% 2 Financial strengthvery low18
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 1.10 17 Interest coverage 0.66 10 Net debt/EBITDAcounts in reverse: lower means more financial strength 4.30 6 Current ratio 1.58 39 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong80
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +16.01% 74 Relative strength (3 months) +53.67% 99 Relative strength (6 months) +13.83% 83 Distance from 200-day average −0.57% 64 Riskvery high93
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 55.9% 90 Volatility (60 days) 152.7% 98 Beta (1 year) 2.54 93
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Diagnosticos da America is cheaper than similar companies
Diagnosticos da America's Forward P/E: 12.8, −28% against the median of a group of 11 similar companies (17.9).
Compared with 11 similar companies
| Metric | Diagnosticos da America | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 12.8 | Low | |
| Operating margin | 10.9% | Low | |
| ROE | -10.7% | Low | |
| Debt/equity | 1.10 | High | |
| Price/book | 0.58 | Low |
Grey band: the middle half of the group; tick: the median; dot: Diagnosticos da America. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
R$2.41B
Latest quarter · Q3 2026
Net income
R$173.34M
Latest quarter · Q3 2026
Quarterly net margin
7.2%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- R$4.07B
- EPS
- -R$0.65
- Volume
- 1.38M
- Daily trading
- €1.23M
How Diagnosticos da America is changing
All resultsRevenue grew 9.7% a year on average over the last 5 years
Operating margin rose from 7.7% to 9.0%
Shares outstanding up 161.1% in 5 years
Returns
Diagnosticos da America returns with dividends
R$1,000 invested in Diagnosticos da America 5 years ago, on November 19, 2021, would be worth R$88 today with dividends reinvested: −91.20% in total, −38.51% per year. On price alone it would be R$87 (−91.28%).
| Period | Diagnosticos da America | Ibovespa | R$1,000 becomes |
|---|---|---|---|
| 1 month | −38.49% | −18.87% | R$615 |
| 6 months | +8.67% | −4.53% | R$1,087 |
| Year to date | −28.19% | +3.26% | R$718 |
| 1 year | +16.01% | +7.08% | R$1,160 |
| 3 years | −68.32% | +31.94% | R$317 |
| 5 years | −91.20% | +61.48% | R$88 |
| 10 years | −81.53% | +172.43% | R$185 |
Over the last 6 months it has done better than 43% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Ibovespa: with dividends. Calculate your investment
The chart in detail
Diagnosticos da America: technical analysis
Diagnosticos da America shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 98.4% below its all-time closing high (R$199.00, January 19, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 44
- Between 30 and 70
- vs 200-session average
- −0.57%
Support and resistance
Price areas where Diagnosticos da America has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceR$3.88+18.87%2 touches, last on March 25, 2026
- ResistanceR$3.61+10.82%7 touches, last on November 11, 2026
- ResistanceR$3.27+0.31%2 touches, last on July 24, 2026
- Last priceR$3.26
- SupportR$2.90−11.04%8 touches, last on September 8, 2026
- SupportR$2.48−24.01%7 touches, last on November 3, 2026
Volatility and risk
Over the last year it has moved more than the Ibovespa.
- Beta (1 year) vs Ibovespa
- 2.54
- Volatility (60 sessions, annualised)
- 152.7%
- Largest fall in the last year
- −55.85%
Close of November 19, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Diagnosticos da America: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Diagnosticos da America has been January: +6.86% on average, positive in 13 years out of 22. The weakest has been March: −4.72% on average, positive in 10 years out of 22. November, the current month, has been positive in 9 years out of 21 (+5.63% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +6.86% | +2.38% | 13 of 22 |
| February | −0.68% | −1.18% | 10 of 22 |
| March | −4.72% | −2.83% | 10 of 22 |
| April | −0.31% | −1.45% | 10 of 22 |
| May | −1.23% | +0.39% | 12 of 22 |
| June | −2.10% | −3.22% | 9 of 22 |
| July | +2.44% | +1.21% | 12 of 22 |
| August | +1.79% | −0.70% | 10 of 22 |
| September | −0.27% | −3.00% | 7 of 22 |
| October | −2.44% | −1.51% | 8 of 22 |
| November | +5.63% | −0.51% | 9 of 21 |
| December | +6.24% | +5.14% | 15 of 22 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Diagnosticos da America and its competitors
Clinical diagnostics, hospital care and oncology services in Brazil and Argentina form the core of Diagnósticos da América S.A., which was founded in 1961 and was formerly known as Laboratório Clínico Delboni Auriemo S.A. until it changed its name in August 2000. The company reports through three segments: hospitals and oncology, national diagnostics operations in Brazil, and international diagnostics operations. Its offering also includes medical services, property and vehicle rental, consultancy and franchise contracting.
- Headquarters
- São Paulo, Brazil
- Employees
- 26,255
- Founded
- 1961
- Chief executive
- Rafael Lucchesi
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Diagnosticos da AmericaDASA3 | $686.17M | 10.9% | — | +8.67% |
| FleuryFLRY3 | $1.97B | 16.0% | 15.0 | +37.09% |
| DiagnostykaDIA | $1.27B | 14.9% | 20.2 | −6.62% |
| DiaSorinDIA | $4.21B | 22.3% | 28.6 | +14.88% |
| Sonic HealthcareSHL | $7.13B | 9.3% | 17.6 | +17.41% |
| WuXi XDC Cayman2268 | $9.64B | 28.1% | 46.6 | +3.47% |
Same industry or related industries, similar size. Compare Diagnosticos da America with its competitors · Full profile
